Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Open-label long-term amlitelimab study in moderate-to-severe atopic dermatitis
NL-OMON59458Phase 2Active, not recruiting
- Sponsor
- Sanofi
- Start
- Nov 2023
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 2 trial of amlitelimab, sponsored by Sanofi. Started Nov 2023; status: active, not recruiting.
02
Drugs
amlitelimab
Beyond the preview
Go deeper on NL-OMON59458.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON59458.